Financials Pfizer, Inc.

Equities

PFE

US7170811035

Pharmaceuticals

Market Closed - Nyse Other stock markets 04:00:02 2024-12-10 pm EST			Pre-market 06:55:27 pm
25.57 ^USD	-2.03%		25.72	+0.59%

Dec. 06	Pfizer: to present its latest data to ASH and SABCS	CF
Dec. 05	Sector Update: Health Care Stocks Retreat Late Afternoon	MT

Projected Income Statement: Pfizer, Inc.

income-statement-evolution-chart PFIZER-INC

Fiscal Period: Dicembre	2019	2020	2021	2022	2023	2024	2025	2026
Net sales ¹	51,750	41,908	81,288	100,330	58,496	62,911	63,341	63,846
Change	-	-19.02%	93.97%	23.43%	-41.7%	7.55%	0.68%	0.8%
EBITDA ¹	21,097	17,801	25,426	42,336	15,590	24,872	25,194	26,203
Change	-	-15.62%	42.83%	66.51%	-63.18%	59.54%	1.29%	4%
EBIT ¹	19,420	13,024	20,235	37,272	9,300	20,656	20,879	21,902
Change	-	-32.94%	55.37%	84.2%	-75.05%	122.11%	1.08%	4.9%
Interest Paid ¹	-1,574	-1,449	-1,291	-1,238	-2,209	-3,011	-2,789	-2,683
Earnings before Tax (EBT) ¹	17,682	7,497	24,311	34,729	1,058	11,511	15,079	15,819
Change	-	-57.6%	224.28%	42.85%	-96.95%	988.02%	30.99%	4.91%
Net income ¹	16,273	9,616	21,979	31,372	2,119	9,310	12,481	13,392
Change	-	-40.91%	128.57%	42.74%	-93.25%	339.38%	34.06%	7.3%
Announcement Date	1/28/20	2/2/21	2/8/22	1/31/23	1/30/24	-	-	-

¹USD in Million

Estimates

Fiscal Period: December	2019 Q4	2020 Q1	2020 Q2	2020 Q3	2020 Q4	2021 Q1	2021 Q2	2021 Q3	2021 Q4	2022 Q1	2022 Q2	2022 Q3	2022 Q4	2023 Q1	2023 Q2	2023 Q3	2023 Q4	2024 Q1	2024 Q2	2024 Q3	2024 Q4	2025 Q1	2025 Q2	2025 Q3	2025 Q4
Net sales ¹	12,688	12,028	11,801	12,131	11,684	14,582	18,977	24,094	23,838	25,661	27,742	22,638	24,290	18,282	12,734	13,232	14,249	14,879	13,283	17,702	17,291	14,335	13,840	15,500	20,515
Change	-	-5.2%	-1.89%	2.8%	-3.68%	24.8%	30.14%	26.96%	-1.06%	7.65%	8.11%	-18.4%	7.3%	-24.73%	-30.35%	3.91%	7.69%	4.42%	-10.73%	33.27%	-2.32%	-17.09%	-3.45%	11.99%	32.35%
EBITDA ¹	3,826	5,539	5,279	5,595	3,114	6,850	8,243	9,876	4,403	11,135	13,583	10,325	6,772	9,161	5,156	-65	1,340	7,648	5,906	7,470	4,141	-	-	-	-
Change	-	44.77%	-4.69%	5.99%	-44.34%	119.97%	20.34%	19.81%	-55.42%	152.9%	21.98%	-23.99%	-34.41%	35.28%	-43.72%	-	-	470.75%	-22.78%	26.48%	-44.56%	-100%	-	-	-
EBIT ¹	3,418	5,135	4,791	4,333	2,068	5,624	6,746	8,516	3,126	9,948	12,408	9,142	5,253	7,674	3,583	-1,625	-330	5,912	4,175	7,035	3,411	5,127	3,737	5,637	-
Change	-	50.23%	-6.7%	-9.56%	-52.27%	171.95%	19.95%	26.24%	-63.29%	218.23%	24.73%	-26.32%	-42.54%	46.09%	-53.31%	-	-79.69%	-	-29.38%	68.5%	-51.51%	50.3%	-27.11%	50.84%	-100%
Charge d'intérêts ¹	-	-	-	-416	-	-	-	-	-315	-324	-295	-311	-313	-320	-510	-695	-689	-792	-781	-783	-699	-	-	-	-
Earnings before Tax (EBT) ¹	-	-	-	-	-	-	-	-	-	9,050	-	-	5,231	-	-	-3,352	-4,129	3,421	-103	4,715	2,104	-	-	-	-
Change	-	-	-	-	-	-	-	-	-	-	-100%	-	-	-100%	-	-	23.18%	-	-	-	-55.38%	-100%	-	-	-
Net income ¹	-337	3,401	-	2,194	594	4,877	5,563	8,146	3,393	7,864	9,906	8,608	4,995	5,543	2,327	-2,382	-3,369	3,115	41	4,465	1,049	-	-	-	-
Change	-	-	-100%	-	-72.93%	721.04%	14.07%	46.43%	-58.35%	131.77%	25.97%	-13.1%	-41.97%	10.97%	-58.02%	-	41.44%	-	-98.68%	10,790.24%	-76.51%	-100%	-	-	-
Announcement Date	1/28/20	4/28/20	7/28/20	10/27/20	2/2/21	5/4/21	7/28/21	11/2/21	2/8/22	5/3/22	7/28/22	11/1/22	1/31/23	5/2/23	8/1/23	10/31/23	1/30/24	5/1/24	7/30/24	10/29/24	-	-	-	-	-

¹USD in Million

Estimates

Forecast Balance Sheet: Pfizer, Inc.

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026
Net Debt ¹	42,320	27,615	7,367	13,097	59,198	58,242	52,128	47,219
Change	-	-34.75%	-73.32%	77.78%	352%	-1.61%	-10.5%	-9.42%
Announcement Date	1/28/20	2/2/21	2/8/22	1/31/23	1/30/24	-	-	-

¹USD in Million

Estimates

Cash Flow Forecast: Pfizer, Inc.

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026
CAPEX ¹	2,176	2,252	2,711	3,236	3,907	2,774	3,022	3,027
Change	-	3.49%	20.38%	19.37%	20.74%	-28.99%	8.92%	0.15%
Free Cash Flow (FCF) ¹	10,412	12,151	29,869	26,031	4,793	10,154	16,871	17,315
Change	-	16.7%	145.82%	-12.85%	-81.59%	111.86%	66.15%	2.63%
Announcement Date	1/28/20	2/2/21	2/8/22	1/31/23	1/30/24	-	-	-

¹USD in Million

Estimates

Forecast Financial Ratios: Pfizer, Inc.

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026
Profitability
EBITDA Margin (%)	40.77%	42.48%	31.28%	42.2%	26.65%	39.54%	39.78%	41.04%
EBIT Margin (%)	37.53%	31.08%	24.89%	37.15%	15.9%	32.83%	32.96%	34.3%
EBT Margin (%)	34.17%	17.89%	29.91%	34.61%	1.81%	18.3%	23.81%	24.78%
Net margin (%)	31.45%	22.95%	27.04%	31.27%	3.62%	14.8%	19.7%	20.98%
FCF margin (%)	20.12%	28.99%	36.74%	25.95%	8.19%	16.14%	26.64%	27.12%
FCF / Net Income (%)	63.98%	126.36%	135.9%	82.98%	226.19%	109.07%	135.17%	129.3%
Profitability
ROA	9.96%	5.98%	13.09%	19.92%	4.96%	6.19%	6.37%	7.06%
ROE	25.72%	15.22%	31.3%	43.51%	11.37%	18.96%	17.88%	17.87%
Financial Health
Leverage (Debt/EBITDA)	2.01x	1.55x	0.29x	0.31x	3.8x	2.34x	2.07x	1.8x
Debt / Free cash flow	4.06x	2.27x	0.25x	0.5x	12.35x	5.74x	3.09x	2.73x
Capital Intensity
CAPEX / Current Assets (%)	4.2%	5.37%	3.34%	3.23%	6.68%	4.41%	4.77%	4.74%
CAPEX / EBITDA (%)	10.31%	12.65%	10.66%	7.64%	25.06%	11.15%	11.99%	11.55%
CAPEX / FCF (%)	20.9%	18.53%	9.08%	12.43%	81.51%	27.32%	17.91%	17.48%
Items per share
Cash flow per share ¹	2.218	2.557	5.708	5.105	1.524	2.799	2.961	3.212
Change	-	15.29%	123.19%	-10.56%	-70.15%	83.7%	5.77%	8.49%
Dividend per Share ¹	1.44	1.52	1.56	1.61	1.65	1.665	1.697	1.715
Change	-	5.56%	2.63%	3.21%	2.48%	0.91%	1.94%	1.04%
Book Value Per Share ¹	11.41	11.36	13.73	17.06	15.77	15.63	16	16.5
Change	-	-0.45%	20.91%	24.2%	-7.57%	-0.88%	2.4%	3.14%
EPS ¹	2.87	1.71	3.85	5.47	0.37	1.604	2.152	2.334
Change	-	-40.42%	125.15%	42.08%	-93.24%	333.65%	34.1%	8.47%
Nbr of stocks (in thousands)	5,534,122	5,558,397	5,612,867	5,613,315	5,646,413	5,666,990	5,666,990	5,666,990
Announcement Date	1/28/20	2/2/21	2/8/22	1/31/23	1/30/24	-	-	-